Protracted review period for Exubera

Share this article:
The FDA notified Pfizer and Sanofi-Aventis that it is extending the original review period for Exubera, the companies' experimental inhaled insulin product, by three months.
The period is being prolonged "to review additional technical chemistry data submitted by the companies," the firms said today in a statement.
The PDUFA (Prescription Drug User Fee Act) date of Oct. 27 has been changed to Jan. 27.
In September the FDA's Endocrinologic & Metabolic Drugs Advisory Committee voted 7-2 in favor of approving Exubera, which Pfizer and Sanofi-Aventis are developing with Nektar Therapeutics, despite concerns about potential adverse lung effects.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...